ICCC vs. OCGN, AMRN, AARD, MDWD, TVGN, ANNX, FHTX, SLRN, DSGN, and URGN
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Ocugen (OCGN), Amarin (AMRN), Aardvark Therapeutics (AARD), MediWound (MDWD), Tevogen Bio (TVGN), Annexon (ANNX), Foghorn Therapeutics (FHTX), Acelyrin (SLRN), Design Therapeutics (DSGN), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.
ImmuCell vs. Its Competitors
Ocugen (NASDAQ:OCGN) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
Ocugen currently has a consensus price target of $6.00, suggesting a potential upside of 417.24%. Given Ocugen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocugen is more favorable than ImmuCell.
ImmuCell has a net margin of -15.99% compared to Ocugen's net margin of -532.51%. ImmuCell's return on equity of -15.32% beat Ocugen's return on equity.
ImmuCell received 6 more outperform votes than Ocugen when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 71.43% of users gave Ocugen an outperform vote.
In the previous week, ImmuCell had 1 more articles in the media than Ocugen. MarketBeat recorded 4 mentions for ImmuCell and 3 mentions for Ocugen. Ocugen's average media sentiment score of 0.74 beat ImmuCell's score of 0.57 indicating that Ocugen is being referred to more favorably in the media.
ImmuCell has higher revenue and earnings than Ocugen. ImmuCell is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.
10.3% of Ocugen shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 4.4% of Ocugen shares are owned by company insiders. Comparatively, 6.6% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Ocugen has a beta of 4.2, meaning that its stock price is 320% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.
Summary
ImmuCell beats Ocugen on 11 of the 18 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
This page (NASDAQ:ICCC) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ICCC Stock Free ICCC Stock Alerts